2nd Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Period 2nd Quarter 2013 Filed Jul 19, 2013 Signed by Francesca Fierro O'Reilly, Vice President, Government Relations

Official filing

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
AMERICAN CLINICAL LABORATORY ASSN
Client
AMERICAN CLINICAL LABORATORY ASSN
Income
—
Expenses
$206,134
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 19, 2013 $206,134 Replaced
2nd Quarter - Amendment Feb 20, 2014 $206,134 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); President of the U.S.; Office of Management & Budget (OMB); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); SENATE

Health Issues HCR

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; President of the U.S.; Government Accountability Office (GAO); SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); President of the U.S.; Government Accountability Office (GAO); Congressional Budget Office (CBO); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC)

Medical/Disease Research/Clinical Labs MED

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); President of the U.S.

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.